Notable Tuesday Option Activity: SMCI, VST, MRK

Vistra Corp (VST) and Merck & Co Inc (MRK) both exhibited unusually high options trading volumes today, with VST's options volume reaching 68.3% of its average daily share volume and MRK's at 51.2%. Notably, VST's $195 call option expiring December 2025 and MRK's $85 call option expiring October 2025 saw particularly concentrated activity, indicating significant speculative or directional interest around these specific price targets and time horizons.

Analysis

Vistra Corp (VST) and Merck & Co Inc (MRK) both experienced a significant surge in options market activity, indicating heightened investor positioning. VST's options volume of 33,247 contracts represented a substantial 68.3% of its average daily share volume, signaling that derivative trading was exceptionally high relative to the underlying stock's liquidity. The concentration of this activity in the long-dated December 19, 2025, $195 strike call option, with 5,800 contracts traded, suggests a specific and highly speculative bullish bet on significant price appreciation over the next 18 months. Similarly, MRK's options volume of 64,393 contracts accounted for 51.2% of its average daily share volume. The notable activity was in the October 03, 2025, $85 strike call, which saw 10,423 contracts traded, indicating a large-scale directional play or hedging strategy being established with a long-term horizon. The neutral sentiment score confirms this report is a factual observation of market flows rather than an opinion-driven piece, highlighting that market participants are making significant, targeted bets on the future of these two companies.

Key Decisions for Investors

• The unusually high and concentrated call option volume in both VST and MRK should prompt investors to investigate potential undisclosed catalysts, as this level of activity often precedes significant company-specific or sector-wide news.
• For Vistra Corp, the large-scale buying of far out-of-the-money, long-dated calls suggests strong speculative bullish sentiment; investors should monitor for developments that could fundamentally re-rate the stock toward the $195 target.
• Regarding Merck, the substantial volume in the October 2025 $85 calls indicates a significant bullish position being built, which could be interpreted as a signal of institutional confidence in the company's long-term pipeline and growth prospects.